These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1189 related items for PubMed ID: 28222269

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
    Harris JK, Wagner BD, Zemanick ET, Robertson CE, Stevens MJ, Heltshe SL, Rowe SM, Sagel SD.
    Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor.
    Ronan NJ, Einarsson GG, Twomey M, Mooney D, Mullane D, NiChroinin M, O'Callaghan G, Shanahan F, Murphy DM, O'Connor OJ, Shortt CA, Tunney MM, Eustace JA, Maher MM, Elborn JS, Plant BJ.
    Chest; 2018 Feb; 153(2):395-403. PubMed ID: 29037527
    [Abstract] [Full Text] [Related]

  • 6. Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor.
    Einarsson GG, Ronan NJ, Mooney D, McGettigan C, Mullane D, NiChroinin M, Shanahan F, Murphy DM, McCarthy M, McCarthy Y, Eustace JA, Gilpin DF, Elborn JS, Plant BJ, Tunney MM.
    J Cyst Fibros; 2021 Sep; 20(5):747-753. PubMed ID: 33549519
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.
    Guimbellot JS, Baines A, Paynter A, Heltshe SL, VanDalfsen J, Jain M, Rowe SM, Sagel SD, GOAL-e2 Investigators.
    J Cyst Fibros; 2021 Mar; 20(2):213-219. PubMed ID: 33249004
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
    Guerra L, D'Oria S, Favia M, Castellani S, Santostasi T, Polizzi AM, Mariggiò MA, Gallo C, Casavola V, Montemurro P, Leonetti G, Manca A, Conese M.
    Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
    [Abstract] [Full Text] [Related]

  • 14. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation.
    Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes D.
    J Cyst Fibros; 2015 Jan; 14(1):84-9. PubMed ID: 25049054
    [Abstract] [Full Text] [Related]

  • 15. Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR.
    Birket SE, Davis JM, Fernandez-Petty CM, Henderson AG, Oden AM, Tang L, Wen H, Hong J, Fu L, Chambers A, Fields A, Zhao G, Tearney GJ, Sorscher EJ, Rowe SM.
    Am J Respir Crit Care Med; 2020 Nov 01; 202(9):1271-1282. PubMed ID: 32584141
    [Abstract] [Full Text] [Related]

  • 16. Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections.
    Durfey SL, Pipavath S, Li A, Vo AT, Ratjen A, Carter S, Morgan SJ, Radey MC, Grogan B, Salipante SJ, Welsh MJ, Stoltz DA, Goss CH, McKone EF, Singh PK.
    mBio; 2021 Dec 21; 12(6):e0314821. PubMed ID: 34903059
    [Abstract] [Full Text] [Related]

  • 17. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
    Kotha K, Clancy JP.
    Ther Adv Respir Dis; 2013 Oct 21; 7(5):288-96. PubMed ID: 24004658
    [Abstract] [Full Text] [Related]

  • 18. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS.
    Ann Pharmacother; 2012 Oct 21; 46(7-8):1065-75. PubMed ID: 22739718
    [Abstract] [Full Text] [Related]

  • 19. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
    Trimble AT, Donaldson SH.
    J Cyst Fibros; 2018 Mar 21; 17(2):e13-e16. PubMed ID: 29079142
    [Abstract] [Full Text] [Related]

  • 20. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM, VX16-659-101 Study Group.
    N Engl J Med; 2018 Oct 25; 379(17):1599-1611. PubMed ID: 30334693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.